Triple Negative Breast Neoplasms

"Triple Negative Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Descriptor ID	D064726
MeSH Number(s)	C04.588.180.788 C17.800.090.500.788
Concept/Terms	Triple Negative Breast Neoplasms Triple Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Neoplasms ER Negative PR Negative HER2 Negative Breast Neoplasms Triple-Negative Breast Cancer Breast Cancer, Triple-Negative Breast Cancers, Triple-Negative Triple-Negative Breast Cancers Triple-Negative Breast Neoplasm Breast Neoplasm, Triple-Negative Breast Neoplasms, Triple-Negative Triple Negative Breast Neoplasm Triple-Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Cancer ER Negative PR Negative HER2 Negative Breast Cancer Triple Negative Breast Cancer

Below are MeSH descriptors whose meaning is more general than "Triple Negative Breast Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Breast Neoplasms [C04.588.180]
Triple Negative Breast Neoplasms [C04.588.180.788]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Breast Diseases [C17.800.090]
Breast Neoplasms [C17.800.090.500]
Triple Negative Breast Neoplasms [C17.800.090.500.788]

Below are MeSH descriptors whose meaning is related to "Triple Negative Breast Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Triple Negative Breast Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Triple Negative Breast Neoplasms" by people in this website by year, and whether "Triple Negative Breast Neoplasms" was a major or minor topic of these publications.

Bar chart showing 41 publications over 12 distinct years, with a maximum of 9 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	1	1
2014	2	0	2
2015	4	0	4
2016	2	1	3
2017	3	0	3
2018	3	1	4
2019	8	1	9
2020	3	0	3
2021	2	1	3
2022	3	0	3
2023	3	0	3
2024	3	0	3

Below are the most recent publications written about "Triple Negative Breast Neoplasms" by people in Profiles.

De la Cruz Ku G, Desai A, Hickey A, Valcarcel B, Wareham C, Hernandez A, Arias-Rivera EE, Chambergo-Michilot D, Linshaw D, Ziegler-Rodriguez G, Persing SM, Homsy C, Chatterjee A, Nardello SM. Disparities in Triple Negative Breast Cancer Among Hispanic Population Living in Latin America Versus the United States. J Surg Oncol. 2025 Jun; 131(7):1258-1271.

View in: PubMed
Kumar A, Goel HL, Silva CA, Wang T, Geng Y, Wang M, Goel S, Hu K, Li R, Zhu LJ, Clark JL, Ferreira LM, Brehm MA, FitzGerald TJ, Mercurio AM. Neuropilin-2-expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling. J Clin Invest. 2024 10 01; 134(22).

View in: PubMed
Zhang Y, Wu MJ, Lu WC, Li YC, Chang CJ, Yang JY. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell Metab. 2024 01 02; 36(1):193-208.e8.

View in: PubMed
Tracy KM, Prior S, Trowbridge WT, Boyd JR, Ghule PN, Frietze S, Stein JL, Stein GS, Lian JB. Bromodomain Proteins Epigenetically Regulate the Mitotically Associated lncRNA MANCR in Triple Negative Breast Cancer Cells. Crit Rev Eukaryot Gene Expr. 2024; 34(2):61-71.

View in: PubMed
Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, Del Valle L, Hicks C, Zabaleta J, Golde T, Osborne B, Miele L. Sulindac sulfide as a non-immune suppressive ?-secretase modulator to target triple-negative breast cancer. Front Immunol. 2023; 14:1244159.

View in: PubMed
Bhardwaj PV, Abdou YG. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer. Oncologist. 2023 10 03; 28(10):832-844.

View in: PubMed
Xu Z, Goel HL, Burkart C, Burman L, Chong YE, Barber AG, Geng Y, Zhai L, Wang M, Kumar A, Menefee A, Polizzi C, Eide L, Rauch K, Rahman J, Hamel K, Fogassy Z, Klopp-Savino S, Paz S, Zhang M, Cubitt A, Nangle LA, Mercurio AM. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer. Sci Transl Med. 2023 05 03; 15(694):eadf1128.

View in: PubMed
Carrillo P, Bernal M, T?llez-Quijorna C, Marrero AD, Vidal I, Castilla L, Caro C, Dom?nguez A, Garc?a-Mart?n ML, Quesada AR, Medina MA, Mart?nez-Poveda B. The synthetic molecule stauprimide impairs cell growth and migration in triple-negative breast cancer. Biomed Pharmacother. 2023 Feb; 158:114070.

View in: PubMed
Murthy SRK, Cheng X, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Sci Rep. 2022 03 08; 12(1):4038.

View in: PubMed
Sogunro O, Sayyed AA, Aminpour N, Towfighi P, Maini M, Masanam M, Deldar R, Murray A, De La Cruz L, Greenwalt I, Son JD. Triple negative breast cancer and reconstruction: Predictors of recurrence, complications, and mortality. Breast Dis. 2022; 41(1):343-350.

View in: PubMed

People

Explore

Similar Concepts

Top Journals